Think Outside the Street
Results 31 - 40 of 1709 : Previous 1 2 3 4 5 6 7 8 9 Next
1-Star Stocks Poised to Plunge: Inhibitex?
Market-lagging returns could be written in this one star.
Are Allergan's Numbers Better Than They Look?
Don't just ask, "How much inventory?" Ask, "What kind?"
GSK's New R&D Culture Forces Research Chiefs to Hustle for Support
How is GSK doing?
A panel of outside experts will help decide Inlyta's fate.
GSK Shakes Up R&D Units During High-Profile Review
The big question is whether GSK's new model is panning out for the London-based drug giant.
Do the Shorts Know Something You Don't?
Are these stocks making short work of short sellers?
Why the Street Should Love Eli Lilly's Earnings
All cash flow is not created equal.
Pozen Inks $75 Million Royalty Deal for Treximet
The pharma sells U.S. rights for the migraine drug to Canada's national pension fund.
Here's How Eli Lilly May Be Failing You
Keep your eye on margins.
Why Pfizer May Be About to Take Off
Don't just ask, "How much inventory?" Ask, "What kind?"
BATS data provided in real-time. NYSE, NASDAQ and AMEX data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates and Analyst Ratings provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK